Literature DB >> 31227806

Variability in gene-based knowledge impacts variant classification: an analysis of FBN1 missense variants in ClinVar.

Linnea M Baudhuin1, Michelle L Kluge2, Katrina E Kotzer2, Susan A Lagerstedt2.   

Abstract

Gene-specific knowledge can enhance genetic variant classification, but may not be routinely incorporated into clinical laboratory practice. For example, FBN1 variants associated with Marfan syndrome may be variably classified depending on knowledge of FBN1-specific critical regions. In order to assess variability in classification of FBN1 variants, 674 FBN1 missense variants from 18 ClinVar submitters were compared and reanalyzed using FBN1-specific criteria and ACMG/AMP 2015 guidelines for variant interpretation. Conflicting variant classifications occurred in 30.7% of the missense variants that had multiple submitters. There were 451 classifications of 361 critical residue missense variants, with 80.0% (361/451) classified as likely pathogenic or pathogenic [(L)P]. Non-cysteine critical residue variants were less likely to be classified as (L)P [55.3% (78/141)] than cysteine variants [91.3% (283/310)] and were more likely to lack evidence citing the functional significance of the amino acid impacted. Application of FBN1-specific knowledge allowed for reclassification or discrepancy resolution in 65/361 (18.0%) critical residue variants. There were 522 classifications of 313 unique missense variants not known to impact a critical residue. Of these, 31.6% (165/522) were likely overclassified as either (L)P or uncertain significance (VUS), especially when minor allele frequency (MAF) was taken into account, and we reclassified or resolved classification discrepancies in 128/313 (40.9%) of these variants. Our results provide a refined framework and resource for FBN1 variant classification, and further supports the more global implications of combining gene-based knowledge with ACMG/AMP criteria and appropriate MAF cutoffs for variant classification that extend beyond FBN1.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31227806      PMCID: PMC6777626          DOI: 10.1038/s41431-019-0440-3

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  49 in total

1.  Mutations in calcium-binding epidermal growth factor modules render fibrillin-1 susceptible to proteolysis. A potential disease-causing mechanism in Marfan syndrome.

Authors:  D P Reinhardt; R N Ono; H Notbohm; P K Müller; H P Bächinger; L Y Sakai
Journal:  J Biol Chem       Date:  2000-04-21       Impact factor: 5.157

2.  Consequences of cysteine mutations in calcium-binding epidermal growth factor modules of fibrillin-1.

Authors:  Tillman Vollbrandt; Kerstin Tiedemann; Ehab El-Hallous; Guoqing Lin; Jürgen Brinckmann; Harald John; Boris Bätge; Holger Notbohm; Dieter P Reinhardt
Journal:  J Biol Chem       Date:  2004-05-25       Impact factor: 5.157

Review 3.  Dissecting the fibrillin microfibril: structural insights into organization and function.

Authors:  Sacha A Jensen; Ian B Robertson; Penny A Handford
Journal:  Structure       Date:  2012-02-08       Impact factor: 5.006

4.  In vivo studies of mutant fibrillin-1 microfibrils.

Authors:  Noe L Charbonneau; Eric J Carlson; Sara Tufa; Gerhard Sengle; Elise C Manalo; Valerie M Carlberg; Francesco Ramirez; Douglas R Keene; Lynn Y Sakai
Journal:  J Biol Chem       Date:  2010-06-07       Impact factor: 5.157

5.  The revised Ghent nosology for the Marfan syndrome.

Authors:  Bart L Loeys; Harry C Dietz; Alan C Braverman; Bert L Callewaert; Julie De Backer; Richard B Devereux; Yvonne Hilhorst-Hofstee; Guillaume Jondeau; Laurence Faivre; Dianna M Milewicz; Reed E Pyeritz; Paul D Sponseller; Paul Wordsworth; Anne M De Paepe
Journal:  J Med Genet       Date:  2010-07       Impact factor: 6.318

6.  Tailoring the American College of Medical Genetics and Genomics and the Association for Molecular Pathology Guidelines for the Interpretation of Sequenced Variants in the FBN1 Gene for Marfan Syndrome: Proposal for a Disease- and Gene-Specific Guideline.

Authors:  Laura Muiño-Mosquera; Felke Steijns; Tjorven Audenaert; Ilse Meerschaut; Anne De Paepe; Wouter Steyaert; Sofie Symoens; Paul Coucke; Bert Callewaert; Marjolijn Renard; Julie De Backer
Journal:  Circ Genom Precis Med       Date:  2018-06

7.  A Gly1127Ser mutation in an EGF-like domain of the fibrillin-1 gene is a risk factor for ascending aortic aneurysm and dissection.

Authors:  U Francke; M A Berg; K Tynan; T Brenn; W Liu; T Aoyama; C Gasner; D C Miller; H Furthmayr
Journal:  Am J Hum Genet       Date:  1995-06       Impact factor: 11.025

8.  Solution structure and dynamics of a calcium binding epidermal growth factor-like domain pair from the neonatal region of human fibrillin-1.

Authors:  Rachel S Smallridge; Pat Whiteman; Jörn M Werner; Iain D Campbell; Penny A Handford; A Kristina Downing
Journal:  J Biol Chem       Date:  2003-01-02       Impact factor: 5.157

9.  Effect of mutation type and location on clinical outcome in 1,013 probands with Marfan syndrome or related phenotypes and FBN1 mutations: an international study.

Authors:  L Faivre; G Collod-Beroud; B L Loeys; A Child; C Binquet; E Gautier; B Callewaert; E Arbustini; K Mayer; M Arslan-Kirchner; A Kiotsekoglou; P Comeglio; N Marziliano; H C Dietz; D Halliday; C Beroud; C Bonithon-Kopp; M Claustres; C Muti; H Plauchu; P N Robinson; L C Adès; A Biggin; B Benetts; M Brett; K J Holman; J De Backer; P Coucke; U Francke; A De Paepe; G Jondeau; C Boileau
Journal:  Am J Hum Genet       Date:  2007-07-25       Impact factor: 11.025

10.  ClinGen's RASopathy Expert Panel consensus methods for variant interpretation.

Authors:  Bruce D Gelb; Hélène Cavé; Mitchell W Dillon; Karen W Gripp; Jennifer A Lee; Heather Mason-Suares; Katherine A Rauen; Bradley Williams; Martin Zenker; Lisa M Vincent
Journal:  Genet Med       Date:  2018-03-01       Impact factor: 8.822

View more
  6 in total

1.  Challenges in returning results in a genomic medicine implementation study: the Return of Actionable Variants Empirical (RAVE) study.

Authors:  David C Kochan; Erin Winkler; Noralane Lindor; Gabriel Q Shaibi; Janet Olson; Pedro J Caraballo; Robert Freimuth; Joel E Pacyna; Carmen Radecki Breitkopf; Richard R Sharp; Iftikhar J Kullo
Journal:  NPJ Genom Med       Date:  2020-05-04       Impact factor: 8.617

2.  Comprehensive Genetic Analysis of RASopathy in the Era of Next-Generation Sequencing and Definition of a Novel Likely Pathogenic >KRAS Variation.

Authors:  Selma Demir; Hümeyra Yaşar Köstek; Aslıhan Sanrı; Ruken Yıldırım; Fatma Özgüç Çömlek; Sinem Yalçıntepe; Murat Deveci; Emine İkbal Atlı; Engin Atlı; Damla Eker; Hakan Gürkan; Filiz Tütüncüler Kökenli
Journal:  Mol Syndromol       Date:  2022-01-07

3.  Patient perspectives on variant reclassification after cancer susceptibility testing.

Authors:  Colin M E Halverson; Laurie M Connors; Bronson C Wessinger; Ellen W Clayton; Georgia L Wiesner
Journal:  Mol Genet Genomic Med       Date:  2020-04-24       Impact factor: 2.183

4.  Exonic splicing code and protein binding sites for calcium.

Authors:  Reuben J Pengelly; Dara Bakhtiar; Ivana Borovská; Jana Královičová; Igor Vořechovský
Journal:  Nucleic Acids Res       Date:  2022-06-10       Impact factor: 19.160

5.  Whole exome sequencing identifies rare coding variants in novel human-mouse ortholog genes in African individuals diagnosed with non-syndromic hearing impairment.

Authors:  Oluwafemi G Oluwole; Kevin K Esoh; Edmond Wonkam-Tingang; Noluthando Manyisa; Jean Jacques Noubiap; Emile R Chimusa; Ambroise Wonkam
Journal:  Exp Biol Med (Maywood)       Date:  2020-09-30

6.  Challenges in returning results in a genomic medicine implementation study: the Return of Actionable Variants Empirical (RAVE) study.

Authors:  David C Kochan; Erin Winkler; Noralane Lindor; Gabriel Q Shaibi; Janet Olson; Pedro J Caraballo; Robert Freimuth; Joel E Pacyna; Carmen Radecki Breitkopf; Richard R Sharp; Iftikhar J Kullo
Journal:  NPJ Genom Med       Date:  2020-05-04       Impact factor: 8.617

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.